Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea

Abstract Background Intestinal Behçet’s disease (BD) is characterized by typical gastrointestinal ulcers in patients with BD followed by complications such as bleeding, perforation and fistula. Biologic agents are currently under active investigation to delay the disease course. Various data regardi...

Full description

Bibliographic Details
Main Authors: Jongwook Yu, Sung Jae Shin, Yune-Jung Park, Hyung Wook Kim, Bo-In Lee, Byong Duk Ye, Geun-Tae Kim, Sung Kook Kim, Joo Sung Kim, Young-Ho Kim, Seonjeong Jeong, Jae Hee Cheon
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Gastroenterology
Subjects:
Online Access:https://doi.org/10.1186/s12876-023-03090-x
_version_ 1827399478752051200
author Jongwook Yu
Sung Jae Shin
Yune-Jung Park
Hyung Wook Kim
Bo-In Lee
Byong Duk Ye
Geun-Tae Kim
Sung Kook Kim
Joo Sung Kim
Young-Ho Kim
Seonjeong Jeong
Jae Hee Cheon
author_facet Jongwook Yu
Sung Jae Shin
Yune-Jung Park
Hyung Wook Kim
Bo-In Lee
Byong Duk Ye
Geun-Tae Kim
Sung Kook Kim
Joo Sung Kim
Young-Ho Kim
Seonjeong Jeong
Jae Hee Cheon
author_sort Jongwook Yu
collection DOAJ
description Abstract Background Intestinal Behçet’s disease (BD) is characterized by typical gastrointestinal ulcers in patients with BD followed by complications such as bleeding, perforation and fistula. Biologic agents are currently under active investigation to delay the disease course. Various data regarding infliximab are available, but there is relatively lack of data regarding adalimumab. Methods This was a multicenter, real-world prospective observational study to evaluate the effectiveness and safety of adalimumab in intestinal BD. The primary endpoint was disease activity at each follow up, including disease activity index for intestinal Behçet’s disease (DAIBD), serum C-reactive protein (CRP) level, and endoscopic findings. The secondary endpoint was the incidence of adverse drug reactions (ADRs). Results A total of 58 patients were enrolled and 8 of them were excluded. Adverse events were reported in 72.0% of patients with 122 events. ADRs were reported in 24.0% with 28 events. For adverse events, arthralgia was most commonly reported (13.1%: 16/122) and only one experienced critical adverse event (0.82%, 1/122: death due to stroke). On multivariable regression analysis, a longer disease duration was significantly associated with decreased ADRs [Odds ratio 0.976 (0.953–0.999, 95% CI); p = 0.042]. Clinical response rates as assessed by DAIBD were 90.9% at Week 12 and 89.7% at Week 56, respectively. The mean serum CRP level at baseline was significantly decreased after 12 weeks (3.91 ± 4.93 to 1.26 ± 2.03 mg/dL; p = 0.0002). Conclusion Adalimumab was found to be safe and effective in Korean patients with intestinal BD. A longer disease duration was significantly associated with decreased ADRs.
first_indexed 2024-03-08T19:46:33Z
format Article
id doaj.art-9d039b74ea4c4de78b7af424d3b64c76
institution Directory Open Access Journal
issn 1471-230X
language English
last_indexed 2024-03-08T19:46:33Z
publishDate 2023-12-01
publisher BMC
record_format Article
series BMC Gastroenterology
spelling doaj.art-9d039b74ea4c4de78b7af424d3b64c762023-12-24T12:20:22ZengBMCBMC Gastroenterology1471-230X2023-12-012311910.1186/s12876-023-03090-xEffectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South KoreaJongwook Yu0Sung Jae Shin1Yune-Jung Park2Hyung Wook Kim3Bo-In Lee4Byong Duk Ye5Geun-Tae Kim6Sung Kook Kim7Joo Sung Kim8Young-Ho Kim9Seonjeong Jeong10Jae Hee Cheon11Department of Internal Medicine, Institute of Gastroenterology, Yonsei University College of MedicineDepartment of Gastroenterology, Ajou University School of MedicineDivision of Rheumatology, Department of Internal Medicine, St. Vincent’s Hospital, The Catholic University of KoreaDepartment of Internal Medicine, Pusan National University Yangsan HospitalDivision of Gastroenterology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of KoreaDepartment of Gastroenterology and Inflammatory Bowel Disease Center, Asan Medical Center, University of Ulsan College of MedicineDepartment of Internal Medicine, Kosin University College of MedicineDepartment of Internal Medicine, Kyungpook National University HospitalDepartment of Internal Medicine and Liver Research Institute, Seoul National University College of MedicineDepartments of Medicine, Samsung Medical Center, Sungkyunkwan University School of MedicineAbbVie LtdDepartment of Internal Medicine, Institute of Gastroenterology, Yonsei University College of MedicineAbstract Background Intestinal Behçet’s disease (BD) is characterized by typical gastrointestinal ulcers in patients with BD followed by complications such as bleeding, perforation and fistula. Biologic agents are currently under active investigation to delay the disease course. Various data regarding infliximab are available, but there is relatively lack of data regarding adalimumab. Methods This was a multicenter, real-world prospective observational study to evaluate the effectiveness and safety of adalimumab in intestinal BD. The primary endpoint was disease activity at each follow up, including disease activity index for intestinal Behçet’s disease (DAIBD), serum C-reactive protein (CRP) level, and endoscopic findings. The secondary endpoint was the incidence of adverse drug reactions (ADRs). Results A total of 58 patients were enrolled and 8 of them were excluded. Adverse events were reported in 72.0% of patients with 122 events. ADRs were reported in 24.0% with 28 events. For adverse events, arthralgia was most commonly reported (13.1%: 16/122) and only one experienced critical adverse event (0.82%, 1/122: death due to stroke). On multivariable regression analysis, a longer disease duration was significantly associated with decreased ADRs [Odds ratio 0.976 (0.953–0.999, 95% CI); p = 0.042]. Clinical response rates as assessed by DAIBD were 90.9% at Week 12 and 89.7% at Week 56, respectively. The mean serum CRP level at baseline was significantly decreased after 12 weeks (3.91 ± 4.93 to 1.26 ± 2.03 mg/dL; p = 0.0002). Conclusion Adalimumab was found to be safe and effective in Korean patients with intestinal BD. A longer disease duration was significantly associated with decreased ADRs.https://doi.org/10.1186/s12876-023-03090-xBehçet’s syndromeAdalimumabInflammatory bowel DiseasesTumor necrosis factor-alpha
spellingShingle Jongwook Yu
Sung Jae Shin
Yune-Jung Park
Hyung Wook Kim
Bo-In Lee
Byong Duk Ye
Geun-Tae Kim
Sung Kook Kim
Joo Sung Kim
Young-Ho Kim
Seonjeong Jeong
Jae Hee Cheon
Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
BMC Gastroenterology
Behçet’s syndrome
Adalimumab
Inflammatory bowel Diseases
Tumor necrosis factor-alpha
title Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
title_full Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
title_fullStr Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
title_full_unstemmed Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
title_short Effectiveness and safety of adalimumab in patients with intestinal Behçet’s disease: a real-world prospective observational study in South Korea
title_sort effectiveness and safety of adalimumab in patients with intestinal behcet s disease a real world prospective observational study in south korea
topic Behçet’s syndrome
Adalimumab
Inflammatory bowel Diseases
Tumor necrosis factor-alpha
url https://doi.org/10.1186/s12876-023-03090-x
work_keys_str_mv AT jongwookyu effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT sungjaeshin effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT yunejungpark effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT hyungwookkim effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT boinlee effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT byongdukye effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT geuntaekim effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT sungkookkim effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT joosungkim effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT younghokim effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT seonjeongjeong effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea
AT jaeheecheon effectivenessandsafetyofadalimumabinpatientswithintestinalbehcetsdiseasearealworldprospectiveobservationalstudyinsouthkorea